Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program
La Jolla, California--(Newsfile Corp. - February 16, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced that Albany Molecular Research ("AMRI") has begun the process of manufacturing the 200g non-GMP demonstration batch of psilocybin. This production step is one of a series of steps in the project plan to manufacture batches of Tryp's...
2021-02-16 12:10 AM EST
Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor
La Jolla, California--(Newsfile Corp. - February 11, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has executed an advisory agreement with Dr. Joel Castellanos, a noted chronic pain physician at UC San Diego Medical Center to join the company's Scientific Advisory Board. He will guide Tryp's clinical development of TRP-8802...
2021-02-11 3:30 AM EST
Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller
La Jolla, California--(Newsfile Corp. - February 8, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp"), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announces it has commenced a collaboration with Dr. Jennifer Miller of the University of Florida as the Principal Investigator for a clinical trial to treat the symptoms associated with eating disorders. Tryp and Dr. Miller have begun designing a Phase 2a...
2021-02-08 6:42 PM EST
Tryp Therapeutics Announces Strategic Investment of $2,000,000
La Jolla, California--(Newsfile Corp. - February 5, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp") is pleased to announce a non-brokered private placement (the "Placement") of 3,333,333 million units (the "Units") at a price of $0.60 per Unit, to raise gross proceeds of approximately $2.0 million. Marc Lustig, founder and former Chairman of Origin House has committed to be a lead participant in the Placement."Tryp is pleased to have this investment led by Marc Lustig, a well-known and...
2021-02-05 3:10 AM EST
Tryp Therapeutics Announces Appointment of Greg McKee as Executive Chairman
La Jolla, California--(Newsfile Corp. - February 3, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp"), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, needs is pleased to announce the appointment of Greg McKee as Executive Chairman.Mr. McKee joined the Board in January of 2021 and brings more than 20 years of biotechnology, life sciences management and venture investment experience to the company. "We...
2021-02-03 4:00 AM EST
Tryp Therapeutics Appoints Dr. Robin Carhart-Harris to Scientific Advisory Board
La Jolla, California--(Newsfile Corp. - February 2, 2021) - Tryp Therapeutics, a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical needs, is pleased to announce that it has added world renowned psychedelic scientist, Dr. Robin Carhart Harris to help lead its Scientific Advisory Board. Dr. Robin Carhart-Harris states, "I'm delighted to be joining the Tryp team. Amidst the rapid growth that is occurring in the psychedelic pharmaceutical...
2021-02-02 3:01 AM EST
Tryp Therapeutics Invited to Present at "Investing in Psychedelics" Conference
La Jolla, California--(Newsfile Corp. - January 19, 2021) - Tryp Therapeutics (CSE: TRYP), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, has been invited to present at the upcoming Investing in Psychedelics Conference hosted by The CSE (Canadian Securities Exchange).Investing in Psychedelics Conference:Date: Wednesday, January 20th, 2021Registration: https://promo.cfnmedia.com/psychedelics“We look...
2021-01-19 7:00 AM EST
Tryp Therapeutics Strengthens Board of Directors with Appointment of Gregory M. McKee
La Jolla, California--(Newsfile Corp. - January 14, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce the appointment of Gregory M. McKee to the Company's board of directors.Mr. McKee brings more than 20 years of biotechnology, life sciences management and leadership and venture investment experience to the company....
2021-01-14 7:00 AM EST
Tryp Therapeutics Invited to Present at Global Healthcare & Psychedelic Conferences
La Jolla, California--(Newsfile Corp. - January 13, 2021) - Tryp Therapeutics, a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has been invited to present at two upcoming industry conferences in January and February 2021. Edison Group: Global Healthcare Conference 2021 Date: January 26-28th, 2021https://www.edisongroup.com/event/open-house-global-healthcare-2021/ Canaccord Genuity:...
2021-01-13 7:00 AM EST
Tryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory Board
La Jolla, California--(Newsfile Corp. - January 7, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has appointed Dr. William K. Schmidt, a noted authority in the development of pain drugs, as a Scientific Advisory Board member. Dr. Schmidt, will aid Tryp in the development of its product candidate TRP-8802 for fibromyalgia and...
2021-01-07 7:00 AM EST
Tryp Therapeutics Appoints Peter Guzzo, PhD, as Vice President, Drug Development
La Jolla, California--(Newsfile Corp. - December 22, 2020) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing compounds for diseases with high unmet medical needs, announced today it has appointed Dr. Peter Guzzo as its Vice President of Drug Development.Dr. Guzzo has devoted his entire 25-year professional career to innovative therapeutics for poorly treated diseases. He has been involved in drug discovery, clinical...
2020-12-22 7:00 AM EST
Tryp Therapeutics Begins Trading on the Canadian Securities Exchange
La Jolla, California--(Newsfile Corp. - December 18, 2020) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company") is pleased to announce that the Company's common shares have commenced trading on the Canadian Securities Exchange ("CSE") under the symbol "TRYP" effective December 18, 2020.James Kuo, MD, CEO states, "Trading on the CSE is a significant milestone in Tryp's mission to transform the treatment of neuropsychiatric diseases with safe and effective psychedelic medicines. All...
2020-12-18 7:00 AM EST
Tryp Therapeutics Completes Initial Public Offering
La Jolla, California--(Newsfile Corp. - December 17, 2020) - Tryp Therapeutics Inc. ("Tryp" or the "Company") is pleased to announce the successful closing of previously announced initial public offering (the "Offering") of units (the "Units"). A total of 20,010,000 Units were sold, including 2,610,000 Units following the exercise in full by the Agent (as defined herein) of its over-allotment option, at a price of $0.25 per Unit for aggregate gross proceeds of $5,002,500.Each Unit consists of...
2020-12-17 11:41 AM EST
Tryp Therapeutics Announces Full Exercise of Over-Allotment Option on Initial Public Offering
La Jolla, California--(Newsfile Corp. - December 14, 2020) - Tryp Therapeutics Inc. ("Tryp" or the "Company") announced today that Canaccord Genuity Corp. (the "Agent"), the sole agent for Tryp's previously announced initial public offering (the "Offering") of 17,400,000 units (the "Units"), has fully exercised its option to increase the size of the Offering by 2,610,000 Units. As a result, the Company will issue a total of 20,010,000 Units, for aggregate gross proceeds of $5,002,500.The...
2020-12-14 7:00 AM EST
Tryp Therapeutics Files Final Prospectus and Announces Initial Public Offering
La Jolla, California--(Newsfile Corp. - December 10, 2020) - Tryp Therapeutics Inc. ("Tryp" or the "Company") is pleased to announce that it has obtained a receipt for its final prospectus, which was filed with the securities regulatory authorities in the provinces of British Columbia, Alberta and Ontario on December 8, 2020 in connection with the initial public offering (the "Offering") of 17,400,000 units of the Company (the "Units") at a price of $0.25 per Unit. The aggregate gross...
2020-12-10 7:00 AM EST
Tryp Appoints Dr. Jim Gilligan, PhD, MBIS, as President and Chief Scientific Officer
La Jolla, California--(Newsfile Corp. - November 12, 2020) - Tryp Therapeutics, a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has appointed Dr. Jim Gilligan as President and Chief Scientific Officer.Dr. Gilligan brings over 30 years of drug development activities including pharmacology, preclinical activities, CMC manufacturing, clinical phase I-III, as well as US and international...
2020-11-12 12:26 PM EST
Tryp Therapeutics Announces Formation of Psilocybin Scientific Advisory Board
La Jolla, California--(Newsfile Corp. - October 6, 2020) - Tryp Therapeutics Inc. ("Tryp" or the "Company"), a pharmaceutical company developing therapeutics specifically targeting diseases with high unmet medical needs announced today the formation of a Scientific Advisory Board ("SAB") for its Psilocybin For Neuropsychiatry ("PFN™") program. The PFN™ SAB is a preeminent group of experts in neuropsychiatry research and clinical care specifically chosen to advise on the Company's TRP-8802,...
2020-10-06 9:00 AM EDT
Tryp Therapeutics Partners with Albany Molecular Research Inc. to Manufacture a Proprietary Psilocybin-based Drug
La Jolla, California--(Newsfile Corp. - August 13, 2020) - Tryp Therapeutics Inc. ("Tryp" or the "Company"), a clinical-stage pharmaceutical company developing therapeutics targeting diseases with high unmet medical needs, announced today it has entered into an agreement with Albany Molecular Research Inc. ("AMRI"), a leading global contract research, development and manufacturing organization, to provide research, development and cGMP manufacturing of a proprietary psilocybin active...
2020-08-13 9:37 AM EDT